Episoder
-
In the lead up to ASCO 2024, we hosted a discussion on the dynamic landscape of oncology today, looking through the lens of this year’s meeting theme: the art and science of cancer care. Within two featured mini panels, we reviewed key trends and innovations and highlighted how intersections between art and science can help us change the face and future of the cancer experience. Touching on areas like advocacy, AI, screening and therapeutic advances, this can’t miss conversation will help us envision a more effective and compassionate future in oncology.
The Art: The art of improving patient care. How industry collaborations, data-based messaging and campaigns and advocacy are helping to reach more patients earlier and more holistically.
Ysabel Duron, Founder, President / Executive Director, The Latino Cancer Institute
Meredith Owen, Chief Revenue Officer, Analytics & Insights Group, Real Chemistry
Shanthi Sivendran, MD, MSCR, MBA, Senior Vice President, Cancer Care Support, American Cancer Society
Jewel Jones, Global Inclusion & Health Equity Practice Leader, Real Chemistry
The Science: The latest therapeutics advancements in oncology. How technology is helping industry better engage providers and democratize science via visualization to help improve outcomes.
HP Balaji, Senior Medical Director and TA Head, Bladder Cancer, Johnson & Johnson Innovative Medicine
Brandon Pletsch, President, Scientific Visualization and Exhibit Experience, Real Chemistry -
Health worker burnout is soaring. A global shortage of providers, an aging population and more complicated Medicare requirements, has increased stress and exhaustion for HCPs. Innovative solutions are needed to ensure high-quality patient care and a sustainable health system. This panel will discuss how AI is helping alleviate pressure on providers while still prioritizing patient privacy and safety. From summarizing journals, to asking an AI agent about dosing or side effects, AI is removing friction so health workers can handle complex engagements, listening, and building relationships.
-
Manglende episoder?
-
With innovative new approaches to diagnosis and treatment in oncology, the cancer mortality rate has dropped year over year for the last decade. But there is still work to be done, especially as we see increasing cancer incidence among certain populations. But what work is happening today that will shape the face of cancer and the patient experience in the future? Wendy Short Bartie (Bristol Myers Squibb), Maimah Karmo (Tigerlily Foundation), and Emily Poe (Real Chemistry) bring together a tapestry of perspectives, from advocacy and equity, research, prevention and holistic care to envision the next 10 years of progress in cancer.
-
While there is undeniable hope for the future of cancer care, systemic barriers still impact access for many patients – particularly those in underserved communities. This session, originally recorded in front of a live audience at SXSW 2024, examines how increasing collaboration and partnerships among organizations that touch all aspects of the cancer journey and reach patients, providers and treatment centers, is critical to expanding access to optimal cancer care and making the goals of the “Cancer Moonshot” a reality. Hear from City of Hope, American Society of Clinical Oncology (ASCO), and American Cancer Society (ACS) about how they are approaching partnerships to create a future where every cancer patient has access to the care they need.
-
In this episode, Suzanne Jacobs, Group President of Medical at Real Chemistry, and Trina Stonner, President of Avant Healthcare, discuss Real Chemistry’s newly announced acquisition of Avant Healthcare, how the two companies came together and have similar ethos of supporting physicians in advancing patient care, and how the future of medical communications will involve a combination of data, creativity, AI, and human expertise.
-
It's time to talk about cancer prevention and early detection. Join us as we explore the importance of early detection and prevention in the fight against cancer with Dr. Karen Knudsen, CEO of the American Cancer Society, and Jim Weiss, Founder and Chairman at Real Chemistry. Tune in to learn about the role of the American Cancer Society in research, advocacy and patient support, the importance of genetic testing in understanding cancer risk and the future of cancer testing and the role of AI.
-
Listen to our latest podcast with Peter Lee, Corporate Vice President, Microsoft Research & Incubations, and Brandon Pletsch, Practice Leader of Scientific Visualization at Real Chemistry, to learn about the applications and implications of generative AI, specifically GPT-4, in healthcare and other fields. They explore public perceptions of AI, its potential benefits and risks, the importance of ethical considerations and regulatory guidelines, and the concept of equitable access to AI in healthcare. Check out the episode to gain insight into how AI can revolutionize fields outside of human language and thought.
-
In this episode, Ajit Singh, PhD, Managing Director and General Partner at Artiman Ventures, shares his insights on various aspects of healthcare, his approach to leadership and decision-making and his thoughts on the future of healthcare. From AI to oncology to neuro technology, Ajit covers it all.
-
Learn more about the inspiring journey of Jason Gardner, Head of Medical at Real Chemistry, and his views on AI and DE&I in healthcare. From his father's struggle with multiple sclerosis to his strategic approach to medical communications, Jason shares his unique perspectives on how diverse thinking and experiences can bring value to the healthcare industry.
-
In this episode, National Pharmaceutical Council (NPC) President and CEO John O'Brien, PharmD, MPH, joins Real Chemistry’s Founder and Chairman, Jim Weiss, to discuss the pharmaceutical industry, the value assessment of medicines, the role of government in drug pricing and the importance of research in healthcare policy. Tune in to get the latest insights on the lack of clarity in government guidelines, the hostile environment for the pharmaceutical industry, the shift in benefits and the rise in patient costs, and the need for more transparency and value-based care.
-
Misinformation in the digital age is a complex problem, but it can be addressed. In this episode, Dr. Geeta Nayyar, former Chief Medical Officer at Salesforce and AT&T, discusses her book, Dead Wrong, and the role of artificial intelligence in healthcare. Tune in to learn more about the importance of trust in the healthcare industry, the role of life sciences companies in combating misinformation and the necessity of health literacy and prevention.
-
In this episode, Javeria Shahab, President of Medical Education at 21GRAMS, a part of Real Chemistry, discusses the challenges and changes in the medical education industry, building effective teams and the importance of empathy in healthcare communications. Get an insider's look into the industry and hear Javeria's advice for those looking to break into the field.
-
In this episode, Dr. Sue Desmond-Hellmann, Member of President Biden’s Council of Advisors on Science and Technology and former CEO of the Bill & Melinda Gates Foundation, Mike Huckman, Global Practice Leader of Executive Communications at Real Chemistry, and Jim Weiss, Founder and Chairman at Real Chemistry, discuss the importance of vaccination, the evolution of cancer treatments and the challenges of clinical trials. They also highlight the need for diverse representation in clinical trials, the implications of the Inflation Reduction Act on the pharmaceutical industry and the influence of science in public health and policymaking.
-
In this episode, Dr. Julie Gerberding, President and CEO of the Foundation for the National Institutes of Health (FNIH), Dr. Jay Bradner, FNIH board member and former President of the Novartis Institutes for Biomedical Research, and Jim Weiss, Founder and Chairman at Real Chemistry and FNIH board member, discuss the power of collaboration, how trust in science is essential for progress, emerging areas in medicine and the challenges of the current healthcare landscape. Listen to the full episode to gain valuable insights and to learn how FNIH is pioneering public-private partnerships to tackle complex health issues.
-
In this episode, Mark Martin, Managing Director at Houlihan Lokey, and Jim Weiss, Founder and Chairman at Real Chemistry, explore the healthcare marketing and commercialization industry, including the impact of data and technology, trends in acquisitions and deals, and the importance of organic growth and innovation.
-
Digital medicine is essential for improving healthcare and addressing issues related to access and equity. In the latest episode, learn about the importance of digital medicine, the challenges and opportunities in the industry and the importance of an integrated evidence plan. Plus, CEO and Co-Founder of the Digital Medicine Society (DiMe), Jennifer Goldsack, shares her thoughts on generative AI and advice for young professionals in healthcare.
As part of DiMe’s upcoming Integrated Evidence Plans for Digital Health Products (IEP) project, leaders in digital health product development, regulation, reimbursement and commercial strategy will partner with payers, purchasers, policymakers, clinicians and patient groups to identify core components of an integrated evidence plan. If you would like to engage in this project and help streamline the path to regulatory and commercial success to optimize health outcomes for the greatest number of patients, learn more and share your interest to join (https://dimesociety.org/access-resources/evidence-defined/#iep-form). -
Did you know that there are more than 100 types of liver diseases that affect 1.5 billion people worldwide? Join us as we explore the importance of collaboration and innovation in addressing liver health issues, the role of digital health and equity, and the future of liver health with Donna Cryer, J.D., Founder, President and CEO of the Global Liver Institute. Get the inside scoop on the latest developments in the field of liver health and how they can improve patient outcomes and access to care.
-
Space exploration and research are rapidly advancing, and life sciences is a key component of this progress. Learn more about the opportunities and developments in space R&D and manufacturing, particularly in the life sciences sector, from Maureen Haverty, VP of Investment at Seraphim Space/Generation Space.
-
Communication is a critical skill for leaders and company culture. In this episode, Real Chemistry Founder and Chairman Jim Weiss is joined by Sally Susman, Chief Corporate Affairs Officer of Pfizer and author of "Breaking Through," who shares her insights on the importance of communication in leadership, building corporate and product brands, and navigating challenging conversations.
- Vis mere